''Metformin in Insulin Resistant LV Dysfunction, a double-blind, placebo-controlled trial'' - TAYSIDE Trial

niversity of Dundee0 个研究点开始时间: 2007年5月30日最近更新: 2017年4月3日

试验速览

暂无简介。

•Patients aged 25-80 yrs with compensated CHF in NYHA functional I-III with evidence of insulin resistance [fasting insulin resistance index values of > 2.7 are said to have insulin resistance].
•Documented Left ventricular dysfunction and/or LV ejection fraction < 35%
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•(i)elderly patients (aged >80 yrs);
•(ii)patients with decompensated CHF (NYHA functional class IV and /or signs of decompensated CHF);
•(iii)renal dysfunction (serum creatinine > 160 mmol/L);
•(iv)Patients who are unable to exercise including patients that will be excluded for reasons of safety or potential effects on exercise performance. Therefore, patients with angina or other cardiac or pulmonary symptoms potentially limiting exercise performance will be excluded.
•(v)Systolic blood pressure >190 mmHg at rest or >250 mmHg with exercise or diastolic blood pressure >95 mmHg at rest or >105 mmHg with exercise will also be a reason for exclusion;
•(vi)Patients with underlying disease likely to limit life span and/or increase risk of interventions will be excluded i.e., cancer; cardiovascular disease .i.e., uncontrolled hypertension: SBP>180 mmHg or DBP, recent stroke, any severe chronic disease (including renal and hepatic disease

发起方

niversity of Dundee